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Molecular pathways leading to the development of Barrett’s esophagus (BE) and 
to the progression from Barrett’s esophagus to esophageal adenocarcinoma 
(EAC) have been the focus of recent research. Surveillance of patients with BE 
relies on regular endoscopic surveillance to detect dysplasia and to diagnose 
carcinoma in an early treatable stage. Poor adherence to the recommended sur-
veillance protocols with extensive sampling, as well as interobserver variability 
in evaluating dysplasia are, however, major drawbacks in this context, emphasiz-
ing the need for molecular biomarkers that may help in risk stratification of BE 
patients.
Definitions of BE vary between countries. In the USA, a diagnosis of Barrett’s 
esophagus is only withheld when normal stratified squamous epithelium of the 
esophagus is replaced by an intestine-like columnar epithelium with goblet cells 
(specialized intestinal metaplasia), whereas in Japan and the United Kingdom BE is 
often used for any columnar mucosa found in the tubular esophagus.
There are different theories concerning the origin of BE and no consensus has 
been reached [1]. Multiple cell sources that may have undergone molecular repro-
gramming can be at the origin of BE. Transdifferentiation is a process in which one 
mature (differentiated) somatic cell type transforms directly into another type of 
mature somatic cell without undergoing an intermediate pluripotent state or pro-
genitor cell type. It seems less probable that this is the origin of BE because it is 
unlikely that a nonproliferating differentiated squamous cell could sustain BE tissue 
indefinitely. Moreover, full phenotypic conversion of a cultured mature squamous 
cell has not yet been demonstrated. Transcommitment, in which undifferentiated 
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progenitor cells in the esophagus that would normally differentiate into squamous 
cells instead differentiate into columnar cells, seems to be the more likely 
hypothesis.
Gene expression arrays showed that expression of genes of both gastric and 
intestinal epithelium can be found in Barrett epithelium. One hypothesis suggests an 
evolution from esophageal squamous epithelium to cardiac type glands and further 
into intestinal glands [2]. Another concept may be the evolution of Barrett glands 
from metaplasia of the stem cells of the proximal columnar gastric or cardiac epi-
thelium [3]. In addition, circulating bone marrow-derived multi-potential stem cells 
have been shown to migrate to the esophagus and contribute to regeneration and 
metaplasia of esophageal epithelium following injury induced by irradiation or 
reflux [4, 5].
Whether its source are esophageal progenitor cells, residual embryonic cells at 
the squamo-columnar junction (SCJ), proximally shifting columnar progenitor cells 
from the gastric cardia, progenitor cells in the submucosal glands or ducts, circulat-
ing bone marrow-derived stem cells or esophageal differentiated squamous cells, 
the cells at the origin of BE would have to undergo molecular reprogramming with 
altered expression of key developmental transcription factors leading to a change in 
the cell’s phenotypic committement [6]. Data exist to support each of these possible 
origins—progenitor cells in the esophagus, progenitor cells proximally shifting 
from the SCJ or cardia or progenitor cells circulating in the bloodstream, as a reac-
tion upon injury—and none can be completely excluded. Esophageal squamous 
epithelial progenitor cells retain the embryonic capacity to switch between squa-
mous and columnar phenotype, but must still undergo molecular reprogramming to 
give rise to specialized intestinal metaplasia. Pathways responsible for columnar 
differentiation, intestinalization, and mucus differentiation from epithelial cells 
with biphenotypic potential are described in the next paragraph.
10.1 Development of BE and Dysplasia
10.1.1  Molecular Pathways Implicated in Development of BE
The esophagus is derived from the embryological foregut. Four main signaling 
pathways in the differentiation of the embryological foregut have been identified 
thus far: the Bone morphogenetic protein (BMP), Hedgehog (HH), Wingless-Type 
MMTV Integration Site Family (WNT), and Retinoic acid (RA) signaling pathways 
(Fig.  10.1) [7]. It has been suggested that dysregulation of these embryological 
signaling pathways is involved in the development of BE.
Bone morphogenic proteins (BMPs) are members of the transforming growth 
factor-β (TGFB) superfamily of ligands [8]. SHH (Sonic hedgehog) is one of the 
three ligands of the HH signaling pathway. The SHH protein is a secretory protein 
that regulates the expression of many genes, among which BMP genes. SHH-BMP 
cell signaling is essential for the development of many organ systems and their 
function is highly conserved between species. The three key transcription factors 
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expressed by these pathways for the regulation of differentiation of foregut epithe-
lium toward a squamous or columnar type are SOX2, p63, and NKX2.1. SOX2 and 
p63 induce squamous differentiation, while NKX2.1 expression is required for 
columnar differentiation [9].
Known risk factors for development of BE are chronic gastroesophageal reflux 
disease (GERD) and obesity. In normal squamous epithelium, the BMP pathway is 
not active [7]. In case of inflammation—as may be caused by GERD—the BMP 
pathway is activated with stromal BMP4 expression, contributing to a columnar 
transdifferentiation of squamous esophageal cells. In vitro studies showed that 
BMP4 induced a shift in the gene expression profile of squamous cells toward that 
of columnar cells, including an important shift of the cytokeratin (CK) expression 
pattern [10]. In BE, CK7 and CK20, markers for glandular differentiation, are 
highly expressed [11]. It is likely that HH signaling also contributes to BE develop-
ment as expression of SHH was found to be increased in biopsies of BE and in a 
mouse model of BE [7]. The HH signaling pathway, as stated above, can activate 
BMP signaling. Furthermore, the HH pathway can also act by inducing epithelial 
SOX9 expression. SOX9 is a transcription factor of columnar-type genes, found to 
induce the expression of columnar-type cytokeratin 8 (CK8) in squamous cells, 
independent of BMP4 [12].
Where SHH and BMP4 are key players for the formation of a simple columnar 
epithelial lining, WNT as well as Notch signaling are subsequently implicated in the 
further differentiation of the intestinal mucosa into crypts and villi [13]. SOX9 pro-
tein is a WNT target expressed in the intestine, where it represses CDX2 and MUC2 
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Fig. 10.1 Molecular pathways leading to the progression from normal squamous epithelium to 
Barrett’s esophagus and adenocarcinoma
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expression and may therefore contribute to the WNT-dependent maintenance of a 
progenitor cell phenotype [14]. CDX1 and CDX2 are homeobox genes playing a 
critical role in differentiation and maintenance of intestinal epithelial functions. 
CDX2 is normally not expressed in the normal esophagus, but nuclear CDX2 as 
well as CDX1 expression can be found in intestinal-type metaplasia [15]. CDX2 
alone is insufficient to induce columnar metaplasia in squamous cells. CDX2 and 
MUC2 expression appear to be late events in columnar cells which already have an 
upregulated BMP4/pSMAD pathway and seem to be mediated by a pSMAD-CDX2 
interaction, and in later stage WNT and Notch signaling [16, 17].
Activity of the retinoic acid (RA) signaling pathway is increased in the develop-
ment of BE [7]. In incubation experiments, RA failed to induce complete columnar 
differentiation in a squamous cell line, but it did increase the expression of MUC2. 
During embryological development, in contrast, RA signaling contributes to squa-
mous differentiation. These opposing effects might be related to differences in reti-
noid receptor subtype expression [7].
10.1.2  Molecular Markers for the Diagnosis of BE
Despite increasing knowledge of the molecular pathways leading to development of 
BE, no markers known to be specific for intestinal columnar epithelium, such as 
DAS1, CDX2, Hep Par 1, Villin, CK 7/20, or any of the MUC molecules (MUC2, 
MUCAC, MUC6), are helpful to distinguish between columnar epithelium of the 
distal esophagus and the proximal stomach [1]. Good communication between gas-
troenterologists and pathologists remains crucial in the identification of patients 
with short- or ultrashort-segment BE. Biopsies of the stomach may help in deter-
mining whether a biopsy with goblet cells in a patient suspicious for ultrashort-
segment BE is indeed indicative of BE. Documentation of chronic gastritis with 
intestinal metaplasia (IM) in the stomach could indicate that the goblet cells in the 
biopsy may be secondary to diffuse chronic gastritis and not be due to BE.
10.1.3  Markers for the Diagnosis of Dysplasia
Several markers have been investigated, such as surface expression of cyclin A by 
immunohistochemistry, the proliferation marker Ki67, DNA content (aneuploidy/
tetraploidy), telomerase activity, genetic mutations (p53, p16, KRAS, APC, 
β-catenin), growth factors, apoptosis inhibitors, cyclooxygenase 2, and alpha-meth-
ylacyl-CoA racemase (AMACR) immunohistochemistry [1, 18–20].
P53 is a transcription factor expressed from the tumor suppressor gene TP53. TP53 
inactivation is the most common genetic alteration in dysplasia and early adenocarci-
noma. Biallelic mutation of this gene will result in aberrant p53 immunohistochemical 
staining properties and in theory should provide an excellent diagnostic tool. Inactivating 
mutations of the p53 gene can be detected by immunohistochemistry, and this has been 
the most extensively studied marker in dysplasia in BE. The frequency of p53 mutation 
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increases in BE neoplasia [21, 22]. However, studies investigating p53 immunohisto-
chemistry suffered from high rates of both false positivity and false negativity and thus 
seemed not appropriate for the confirmation of a histologic diagnosis of dysplasia in 
patients with BE. The fact that studies failed to show unequivocal results may be due to 
different protocols and antibodies used. Recent data however, re-emphasize the value 
of p53 as an ancillary marker in BE. Quality assessment of p53 immunohistochemistry 
and recognition of complete absence of p53 staining as an indication of an inactivating 
mutation of the p53 gene, next to the more common pattern of p53 overexpression, may 
have contributed to better recognition of the value of p53 immunohistochemistry. If there 
is unequivocal dysplasia, p53 immunohistochemistry is not required. Dysplasia in BE 
in a minority of cases occurs without abnormal p53 staining and a definite morphologi-
cal diagnosis of dysplasia should not be altered in case of normal p53 expression. P53 
immunohistochemistry, however, appears to be a very useful marker in difficult cases as it 
improves the reproducibility of definite dysplasia in BE. Unfortunately, p53 is generally 
expressed aberrantly in both low- and high-grade dysplasia, so while appearing a very 
useful marker of dysplasia, its role in the grading of dysplasia is less clear [23].
The WNT signaling pathway is responsible for promoting the intestinal architec-
ture. Activation of the WNT signaling pathway can be observed by overexpression 
of the WNT targets cyclin D1, SOX-9 and c-myc. WNT signaling appeared to play 
a role in progression to dysplasia, especially high-grade dysplasia [24].
Telomere shortening is correlated with cellular senescence and apoptosis. Cancer 
cells can escape apoptotic pathways by activating mechanisms involved in telomere 
elongation and stabilization. Telomerase is responsible for telomere maintenance. 
Inhibition of telomerase leads to shorter telomeres, reduced cell growth, and apop-
tosis. Higher telomerase activity may be an early event in maintaining genomic 
instability, even in the premalignant phase [25].
The frequency of AMACR-immunohistochemical positive staining increases in 
BE neoplasia [26, 27]. This enzyme is found in mitochondria and in peroxisomes. It 
has been described in low- and high-grade dysplasia, as well as in adenocarcinoma. 
Results of two studies were only moderately consistent in their findings [28].
10.1.4  Genome-Wide Association Studies for the Development 
of Barrett’s Esophagus
There is a substantial overlap in the set of genes contributing to the risk of BE and 
adenocarcinoma of the esophagus. Genome-wide association studies have identified 
8 loci within or near MHC, FOXF1, GDF7, TBX5, CRTC1, BARX1, FOXP1, and 
ALDH1A2 associated with the development of BE [29–31].
10 The Role of Molecular Biology in Diagnosis and Follow-Up of Barrett’s Esophagus
106
10.2 Progression to Adenocarcinoma in BE
10.2.1  Molecular Pathways Implicated in the Transition 
of Barrett’s Esophagus to Early Adenocarcinoma
Because BE is common in the population and only a minority of patients develop 
esophageal carcinoma, specific markers for the transition of BE to early adenocar-
cinoma are needed.
The signaling pathways implicated in the differentiation of the embryological 
foregut—the Bone morphogenetic protein (BMP), Hedgehog (HH), Wingless-Type 
MMTV Integration Site Family (WNT), and Retinoic acid (RA) signaling path-
ways—may be implicated in the progression from BE to EAC [7]. During the pro-
gression of BE toward malignancy, the SHH and WNT signaling pathways are 
upregulated while the RA and probably the BMP signaling pathways are downregu-
lated. Further research however is required to further elucidate these issues since 
modulation of these pathways may be an option in the management of development 
of EAC in BE.
10.2.2  Molecular Biology of Progression to Adenocarcinoma
C-myc and cyclins have been implicated as oncogenes, inducing hyperproliferation 
[32]. C-myc is a transcription factor essential for the expression of genes necessary 
for cell proliferation. The incidence of c-myc amplification was reported to increase 
with worsening histopathology [33]. Tumors with c-myc amplification in addition 
were found to show overexpression of COX2 and VEGF, genes involved in angio-
genesis, a process essential for carcinoma development [34]. Cyclins have varying 
expression levels during cell cycle. Dysregulation of key players in the cell cycle 
can lead to tumor growth [32].
The mitogen-activated protein kinase (MAPK) RAS-RAF signaling pathway 
may be implicated in development of BE EAC. However, the phosphatidylinositol 
3-kinase (PI3K) pathway has recently been identified by exome and whole-genome 
sequencing as the most frequently altered oncogenic pathway in esophageal adeno-
carcinoma development [35, 36]. ErbB-2 mutations have been detected, but the role 
of erbB-2 (also called HER2/Neu) in the development of BE and EAC remains 
controversial [37]. The prevalence of HER2 amplification or overexpression has 
been reported to be high in BE and adenocarcinoma of the esophagus [38]. It was 
however also shown that the majority of HER2-amplified gastric as well as esopha-
geal adenocarcinomas harbor secondary oncogenic alterations that can confer resis-
tance to HER2-directed therapy [39]. HER2 and EGFR for example are frequently 
co-amplified and may dimerize with one another [39].
The TGF-β signaling pathway regulating growth inhibition and suppression of 
genomic instability requires the transcription factors SMAD proteins and 
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Runt-related transcription factor 3 (RUNX3). SMAD4 alterations may be stage spe-
cific and although BE and EAC share a common mutational landscape, SMAD4 
mutations are confined to the malignant stage of the disease [40].
Inactivation of tumor suppressor genes p53, p16, p27, and APC has been impli-
cated in the progression of BE to adenocarcinoma. Inactivation of p53 is thought to 
be a mechanism to avoid apoptosis of DNA damaged cells. Overexpression of 
cyclo-oxygenase-2, expression of NF-κβ, and downregulation of 15-lipoxygenase-1 
have also been described, as well as expression of the anti-apoptotic proteins Bcl-2 
and Bcl-XL and the pro-apoptotic protein Bax [41–43].
Aneuploid cells are at risk for neoplastic progression and in progression of BE to 
EAC epithelial cells were demonstrated to express aneuploidy [19].
Enhanced expression of both tumor necrosis factor receptor 1 (TNFR1) and 
TNF-α, its ligand, has been described [44].
Epigenetic changes can lead to altered gene expression without the occurrence of 
mutations or structural variation. Hypermethylation of tumor suppressor genes such 
as APC, CDKN2A, CDH1, transcription factor ESR1 and REPRIMO—involved in 
the p53-mediated cell cycle arrest—has been demonstrated.
Small non-coding microRNAs (miRNAs) capable of degrading target mRNA via 
sequence complementarity have been the subject of many studies as well. miR-21 is 
one of the most expressed microRNAs in EAC [45]. miRNA-375 may be downregu-
lated and is associated with c-myc and TP53 regulation [46]. Other frequently 
reported miRNAs are miR-192, -194, and -96A, that are more expressed with pro-
gression to malignancy, whereas miR-200 and miR-203 are downregulated [47]. 
miRNA could have unique expression profiles in different stages of malignant pro-
gression making them potential diagnostic indicators. miR-25, -99a, -133a, and 
-133b are purely diagnostic and miR-21, -27b, -126, -143, and-145 as a panel can 
be valuable both in diagnosis and prediction of progression [48].
10.2.3  Molecular Markers for the Diagnosis of Progression to EAC
Accumulation of aberrant chromosomal events resulting in aneuploidy, chromo-
somal rearrangements, tumor suppressor inactivation, and activation of oncogenes 
are associated with progression to carcinoma. Especially inactivation of the tumor 
suppressor gene p53, methylation markers, and DNA content (aneuploidy/tetra-
ploidy) have been examined as potential markers to help to identify high-risk 
patients [18–21]. Aberrant p53 expression is associated with an increased risk of 
neoplasia, both overexpression and loss of expression [49]. In the overexpression 
pattern, an intense nuclear staining will be seen because of the accumulation of 
abnormal amounts of the p53 protein, due to mutations creating a protein product 
that is resistant to degradation. Complete lack of p53 labeling can be the result of 
homozygous deletion of the TP53 locus or can be caused by mutations in the TP53 
transcript, accelerating its degradation.
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Normal epithelium—both squamous and non-dysplastic columnar epithelium—
invariably express a low background amount of p53 protein because of ongoing 
DNA surveillance mechanisms, thus providing an internal p53 staining control. It is 
estimated that between 10 and 20% of BE with dysplasia show the so-called null 
mutation pattern with complete absence of staining. P53 function is altered or lost 
by mutation or loss of heterozygosity (LOH). Combination of biomarkers, such as 
DNA content and LOH of p53 and p16 appeared to be a good indicator of neoplastic 
progression [49–51]. Recent data show that aberrant expression of p53  in BE 
appears to be associated with a significantly increased risk of neoplastic progression 
also in non-dysplastic and low-grade dysplastic BE (Fig. 10.2).
10.2.4  Genetic Changes Involved in the Progression 
From BE to EAC
The concept that the evolution of cancer proceeds through a stepwise accumulation 
of genetic alterations in a predictable, linear manner has existed for a long time. It 
fits with phenotypic observations of changes in cell and structure, such as the pro-
gression from metaplastic BE over dysplastic BE to EAC. Consequently, for a long 
time, it was believed that specific genetic alterations would be present at different 
stages of neoplastic progression.
* ♦
*
♦
Fig. 10.2 Tissue section from an EMR (endoscopic mucosal resection) specimen—HE and p53 
immunohistochemistry—with higher magnification of the regions indicated on the right (asterisk) 
and left (filled diamond) end. At the left end, there is an area of p53 overexpression (asterisk) cor-
responding with glands showing high-grade intestinal type dysplasia, while at the right end (filled 
diamond) we can observe an area of complete absence of p53 staining, corresponding in this case 
with glands showing foveolar type dysplasia. Next to the area of p53 overexpression, we recognize 
glands with intestinal metaplasia showing wild-type p53 expression (arrow)
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Joint efforts such as The Cancer Genome Atlas and the International Cancer 
Gene Consortium helped us to understand somatic genetic and epigenetic altera-
tions leading to the development of cancer by carrying out whole-genome and/or 
whole-exome sequencing in different cancer types.
These studies have demonstrated that there are more pathways to develop a 
malignancy by showing the heterogeneity of gene mutations that can occur in can-
cers in the population. We also learned that a tumor does not consist of one type of 
cancer cells, but that there is also intratumoral heterogeneity. With the exception of 
TP 53, few genes appear to be altered in a high number of cancer samples—and a 
large number of genes appear to be altered in only a minority of cases.
It remains hard to identify genetic changes responsible for driving certain events 
in the development of a specific cancer type. In BE associated EAC loci found near 
CRTC1, BARX1, FOXP1, and ALDH1A2 have been associated with development 
of both BE and esophageal adenocarcinoma [29–31]. These observations sustain a 
genetic component of BE and EAC associated with BE.
The mutational load in esophageal adenocarcinoma is high and microsatellite 
instability is rare [52]. Despite a very high mutational load, very few genes were 
altered in more than 20% of cancers. The extensive copy number alterations and 
structural rearrangements found indicate a variety of mutational mechanisms active 
during progression to EAC. The small number of studies that examined BE around 
EAC found clonally related alterations in the precursor and the cancer, indicating that 
the evolution of somatic genomic alterations found in EAC begins in BE [52, 53].
10.2.5  Biomarker Development
Biomarkers with high specificity and sensitivity are needed for a reliable diagnosis 
of carcinoma in its earliest stage and for the identification of patients at risk. Most 
of the preclinical findings are not yet ready for clinical implementation.
As stated before, recent data show that aberrant expression of p53 in BE appears 
to be associated with a significantly increased risk of neoplastic progression also in 
non-dysplastic and low-grade dysplastic BE. If there is unequivocal dysplasia, p53 
immunohistochemistry is not required. Dysplasia in BE in a minority of cases 
occurs without abnormal p53 staining and a definite morphological diagnosis of 
dysplasia should not be altered in case of normal p53 expression. P53 immunohis-
tochemistry, however, appears to be a very useful marker in difficult cases, as aber-
rant expression in this context implies that these patients are at high risk of 
progression and should be managed as such. However, quality assurance of p53 
immunohistochemistry is needed to improve staining method and interpretation. 
Also, further confirmation of these findings are needed, before this can be imple-
mented in daily practice [23, 28].
Some other biomarker panels have been validated in large prospective cohorts. A 
set of methylation markers (p16, RUNX3, HPP1, NELL1, TAC1, SST, AKAP12, 
and CDH13) showed to have a good specificity, but low sensitivity [54]. A 
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chromosomal abnormality panel can include TP53, CDNK2A (p16), LOH, and 
DNA content abnormality [55].
Attempts are made to combine molecular biomarkers with imaging techniques, 
in order to target biopsies more properly [56]. The cytosponge is an example of a 
tool developed to acquire reliable material in a minimally invasive way [57]. 
Coupled with immunohistochemistry for Trefoil Factor 3 it may identify patients 
with reflux symptoms who warrant endoscopy to diagnose BE. miRNA panels 
could be useful because the tissue-specific gene regulation may allow the develop-
ment of a test based on a noninvasive blood collection [58].
None of these biomarker panels are ready for routine use. Studies evaluating 
reproducibility, specificity, and sensitivity are warranted. Biomarkers need to 
address the issues of under- and overdiagnosis and have to be validated for specific 
stages during progression to EAC.
 Conclusions
Barrett’s esophagus probably develops as a result of transcommitment, in which 
progenitor cells in the esophagus that normally would differentiate into squa-
mous cells instead differentiate into columnar cells. The pathways responsible 
for columnar differentiation, intestinalization, and mucus differentiation from 
epithelial cells have largely been described. However, there are still many issues 
at the molecular level that need to be resolved in order to allow to develop novel 
molecular therapies.
Molecular markers for the diagnosis of dysplasia and early adenocarcinoma 
have been described, p53 being the most intensively studied. However, all mark-
ers suffer from high rates of both false positivity and negativity. Studies failed to 
show unequivocal results, possibly due to different protocols and antibodies 
used. More and more data confirm that aberrant expression of p53 in BE is asso-
ciated with a significantly increased risk of neoplastic progression also in non-
dysplastic and low-grade dysplastic BE. Prospective validation studies are still 
warranted, even for the most promising markers, before they may be used as 
reliable biomarkers. Quality assurance of p53 immunohistochemistry is needed 
to improve staining method and interpretation, before this can be implemented in 
daily practice.
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